Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Citizens analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $19 price target.